SCHEMBL5839510

SCHEMBL5839510

COc1ccc(I)c(OC)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
BRD9 Q9H8M2 1/20 0.38
BRD7 Q9NPI1 1/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
PDE10A Q9Y233 3/20 0.37
CYP1A2 P05177 2/20 0.36
KMT2A Q03164 2/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
NNMT P40261 1/20 0.36
RECQL P46063 1/20 0.36
ERN1 O75460 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31373313 0.80 CCR4 (0.33) POLBTDP1ALDH1A1CYP1A2
SCHEMBL2413148 0.80 CCR4 (0.33) POLBTDP1ALDH1A1CYP1A2
SCHEMBL22168317 0.77 APOBEC3A (0.40) HPGDSMN1; SMN2HSD17B10ALDH1A1RAB9A
SCHEMBL18774086 0.77 NNMT (0.48) POLBTDP1BRD9BRD7ALDH1A1
SCHEMBL17276010 0.76 BRD9 (0.56) POLBTDP1BRD9BRD7HPGD
SCHEMBL31438401 0.76 BRD9 (0.56) POLBTDP1BRD9BRD7HPGD
SCHEMBL12677821 0.76 CYP1A2 (0.39) POLBTDP1PDE10ACYP1A2KMT2A
SCHEMBL22953996 0.76 HTT (0.37) POLBTDP1HPGDTSHRSMN1; SMN2
SCHEMBL5925877 0.76 POLB (0.36) POLBTDP1PDE10ACYP1A2KMT2A
SCHEMBL2461286 0.76 POLB (0.36) POLBTDP1ALDH1A1HTTPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9617255-B2 Organic electroluminescent element, and illumination device and display device each comprising the element Konica Minolta, Inc. (JP) 2017-04-11 US disclosed
US-8466163-B2 Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization BIONOMICS LIMITED (AU) 2013-06-18 US disclosed
US-8466163-B2 Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization BIONOMICS LIMITED (AU) 2013-06-18 US disclosed
US-20100048591-A1 CHEMICAL COMPOUNDS AND PROCESSES BIONOMICS LIMITED (AU) 2010-02-25 US disclosed
US-20100048591-A1 CHEMICAL COMPOUNDS AND PROCESSES BIONOMICS LIMITED (AU) 2010-02-25 US disclosed
US-7122699-B2 Process for preparing organic boronic acid derivatives using diboronic acid BORON MOLECULAR LIMITED (AU) 2006-10-17 US disclosed
US-6939985-B1 covalently coupling organic compounds by reacting an aromatic ring compound having a halogen or halogen-like substituent at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a base COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2005-09-06 US disclosed
EP-1019414-B1 PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID COMMW SCIENT IND RES ORG (AU) 2005-06-08 EP disclosed
US-6794529-B2 CATALYTIC REACTION OF DIBORANE COMPOUND USING GROUP 8 METAL CATALYST COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2004-09-21 US disclosed
US-20030220520-A1 Process for preparing organic boronic acid derivatives using diboronic acid COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2003-11-27 US disclosed
EP-1224190-A1 SUBSTITUTED DIBORON COMPOUNDS Commonwealth Scientific and Research Organisation (AU) 2002-07-24 EP disclosed
US-6399779-B1 REACTING A HALOGEN AROMATIC DERIVATIVE AT A COUPLING POSITION WITH A DIBORON DERIVATIVE IN THE PRESENCE OF A GROUP 8 METAL CATALYST COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2002-06-04 US disclosed
EP-1019414-A4 PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID COMMW SCIENT IND RES ORG (AU) 2002-05-29 EP disclosed
US-20020032339-A1 ARYL BORATES BORON MOLECULAR LIMITED (AU) 2002-03-14 US disclosed
WO-2001029051-A1 SUBSTITUTED DIBORON COMPOUNDS COMMONWEALTH SCIENTIFIC AND RESEARCH ORGANISATION (AU) 2001-04-26 WO disclosed
CN-1275984-A Process for preparing organic boronic acid derivatives using diboronic acid COMMW SCIENT IND RES ORG (AU) 2000-12-06 CN disclosed
EP-1019414-A1 PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-07-19 EP disclosed
EP-0986541-A1 PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-03-22 EP disclosed
WO-1999012940-A1 PROCESS FOR PREPARING ORGANIC BORONIC ACID DERIVATIVES USING DIBORONIC ACID COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1999-03-18 WO disclosed
WO-1998045265-A1 PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048591-A1 CHEMICAL COMPOUNDS AND PROCESSES LTC4S, HNMT, SQLE POLB 1173/4885TDP1 2699/4885BRD9 3759/4885
US-20030220520-A1 Process for preparing organic boronic acid derivatives using diboronic acid BTD, BRAP, DBF4 POLB 470/4885TDP1 3262/4885BRD9 159/4885
US-20020032339-A1 ARYL BORATES TBCB, HAT1, UBE2B POLB 775/4885TDP1 2369/4885BRD9 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.